Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation

CRISPR offers new hope for many patients and promises to transform the way we think of future therapies. Ensuring safety of CRISPR therapeutics is a top priority for clinical translation and specific recommendations have been recently released by the FDA. Rapid progress in the preclinical and clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Ewaisha, Radwa, Anderson, Karen S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Bioengineering and Biotechnology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978118/
https://www.ncbi.nlm.nih.gov/pubmed/36873375
http://dx.doi.org/10.3389/fbioe.2023.1138596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978118/
https://www.ncbi.nlm.nih.gov/pubmed/36873375
http://dx.doi.org/10.3389/fbioe.2023.1138596

Ejemplares similares